The present invention provides a chimeric antigen receptor (CAR) comprising an antigen-binding domain with an affinity in the range of 50 nM to 500 nM, wherein said affinity comprises component kinetics such that the association rate constant (kon) is greater than or equal to 1×105 M−1 S−1, and/or the dissociation rate constant (koff) is greater than or equal to 0.01 s−1.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.
A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
The present invention provides a method of preparing a population of genetically modified cells which comprise a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR) comprising: (i) providing a starting population of cells; (ii) depleting said starting population of cells which express a target antigen to form a depleted starting population; (iii) selecting for CD4+ and CD8+ cells in the depleted starting population to form a selected population of cells; and (iv) introducing into a cell in the selected population a nucleic acid sequence which encodes a CAR or transgenic TCR against the target antigen.
The present invention provides a chimeric cytokine receptor (CCR) comprising: (i) an exodomain which binds to a ligand selected from a tumour secreted factor, a chemokine and a cell-surface antigen; and (ii) a cytokine receptor endodomain.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
C07K 14/46 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
5.
T-CELL RECEPTOR CONSTANT REGION 1 ANTIBODY OR T-CELL RECEPTOR CONSTANT REGION 2 ANTIBODY
The present invention provides antibodies and polyclonal antibody preparations which bind the intracellular portion of either T-cell receptor constant region 2 (TRBC2) or T-cell receptor constant region 1 (TRBC1). The antibodies can be used to determine whether a T-cell malignancy clonally expresses TRBC1 or TRBC2.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
The present invention provides methods for selecting a bridging therapy for a patient having a B-cell malignancy who is about to receive treatment with CAR-T cells.
The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
8.
COMPOSITIONS AND METHODS COMPRISING ENGINEERED CHIMERIC ANTIGEN RECEPTOR AND MODULATOR OF CAR
There is provided method for making a cell composition which comprises step of transducing a population of cells with a mixture of at least two viral vectors, wherein at least one vector comprises a nucleic acid sequence which encodes a chimeric antigen receptor (CAR); and wherein at least one vector comprises a nucleic acid encoding an activity modulator which modulates the activity of the CAR, of a cell expressing the CAR, or of a target cell. There is also provided a cell composition made by such a method and its use in the treatment of diseases such as cancer.
The present invention relates to FcRH5 binding domains. In particular, the invention provides single domain antibodies, antibody conjugates, chimeric antigen receptors (CARs) and immune cell engagers which comprise such binding domains.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
There is provided a method of treating an autoimmune disease comprising administering to a patient a cell composition made by transducing cells with a mixture of vectors, the mixture comprising: (i) a first vector which expresses a first chimeric antigen receptor (CAR) which binds CD19; and (ii) a second vector which expresses a second CAR which binds B cell maturation antigen (BCMA). There is also provided a method for selectively deleting anti-BCMA CAR-expressing cells and a method for restoring the plasma cell compartment in a patient who has received such a treatment.
The present invention provides a chimeric antigen receptor (CAR) which binds a low density target antigen, which comprises a Fab antigen binding domain. The invention also relates to cells expressing such a CAR and their use in the treatment of disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a cell comprising a chimeric antigen receptor (CAR) and a constitutively active or inducible Signal Transducer and Activator of Transcription (STAT) molecule.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
The present invention provides a process for producing engineered cells, the process comprising: a) providing a starting population comprising at least 400 million cells; activating the cells; b) transducing the starting population with a retroviral vector carrying a transgene of interest; and c) expanding the transduced cells in a culture medium for a maximum of 6 days, or until a target dose is reached; wherein the culture medium does not contain exogenous cytokines.
The present invention relates to a chimeric antigen receptor (CAR) which binds the B- lymphocyte antigen CD19 (Cluster of Differentiation 19) and to use of T cells expressing such a CAR for the treatment of autoimmune diseases, such as systemic lupus erythematosus (SLE)
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable mobile applications for use in enabling
healthcare professionals and patients to access information
on pharmaceutical and medical related products and services. Educational services, including training and coaching
services in the field of medical diseases and disorders and
their treatment; arranging, organising and conducting events
for educational purposes related to oncology, autoimmune
diseases, immunotherapy and cell therapy. Hosting a website featuring non-downloadable software for
providing digital platforms tailored for healthcare
professionals and patients, for web-based scheduling,
consultation, examination, assessment, education,
supervising, monitoring and treatment of patients in a
remote setting, coordinating patients and resources, and
secure messaging to patients and healthcare providers;
software as a service (SaaS) services featuring software for
providing digital platforms tailored for healthcare
professionals and patients, for web-based scheduling,
consultation, examination, assessment, education, monitoring
and treatment of patients in a remote setting, coordinating
patients and resources, and secure messaging to patients and
healthcare provider; platform as a service (PaaS) services
featuring computer software platforms tailored for
healthcare professionals and patients, for web-based
scheduling, consultation, examination, assessment,
education, monitoring and treatment of patients in a remote
setting, coordinating patients and resources, and secure
messaging to patients and healthcare provider; provision of
scientific information via an internet portal. Medical and healthcare services; providing information
related to healthcare, pharmaceutical products, vaccines,
diseases and disorders and treatment options via a website
and platform; medical services related to providing support
for patients and healthcare providers featuring information
in the field of healthcare, oncology, autoimmune diseases,
immunotherapy, cell therapy and pharmaceutical products via
a website and platform; providing medical information via a
website, namely clinical and medical information, including
providing advice on patient specific pharmaceuticals and
cell therapies, disease monitoring and treatment in the
field of oncology, autoimmune diseases, immunotherapy and
cell therapy; provision of information, consultancy and
advisory services relating to all of the aforesaid services.
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medical and veterinary preparations for therapeutic
purposes; preparations for cell therapy; preparations for
gene therapy; preparations for cancer therapies;
preparations for autoimmune diseases; chimeric antigen
receptors (CAR) and therapeutic preparations thereof;
antibodies; preparations for genetically modifying human or
animal cells for medical purposes, including viral vectors;
preparations of blood extracted from humans or animals which
have been adapted for therapeutic purposes; pharmaceutical
preparations; pharmaceutical preparations for use in the
treatment of cancer; pharmaceutical preparations for use in
the treatment of autoimmune diseases; biological
preparations for the treatment of cancer; biological
preparations for use in the treatment of autoimmune
diseases; pharmaceutical and biological preparations for
immunotherapy, including T cell therapy; vaccines. Custom manufacture of therapeutic drugs, namely cell
therapies, preparations to treat autoimmune diseases, cancer
therapies and cancer vaccines. Scientific and technological services and research and
design relating thereto; industrial analysis and research
services; medical and veterinary research services including
the manipulation of cells within a laboratory or research
facility to enable the cells to be used for therapeutic
purposes; scientific research in the development of
autoimmune diseases and new cancer therapies; scientific
research in human and animal cell therapy; scientific
research in human and animal gene therapy; scientific
research into vaccines, including personalised cancer
vaccines; scientific research into vectors and preparations
for manipulating and adapting human and animal cells;
consultancy relating to all the aforesaid services. Medical services; veterinary services; services in the
extraction of human and animal cells from patients;
manipulation of human and animal cells for therapeutic
purposes; reinsertion of cells into human and animal
patients; providing advice and consultancy in the field of
medical and veterinary therapies; providing advice and
consultancy in the field of autoimmune diseases, cancer
therapies and cancer vaccines.
There is provided an anti-GD2 CAR T cell composition, a method for making such a composition and its use in the treatment of diseases such as Neuroblastoma.
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Medical and veterinary preparations for therapeutic purposes; preparations for cell therapy; preparations for gene therapy; preparations for cancer therapies; preparations for autoimmune diseases; chimeric antigen receptors (CAR) and therapeutic preparations thereof; antibodies; preparations for genetically modifying human or animal cells for medical purposes, including viral vectors; preparations of blood extracted from humans or animals which have been adapted for therapeutic purposes; pharmaceutical preparations; pharmaceutical preparations for use in the treatment of cancer; pharmaceutical preparations for use in the treatment of autoimmune diseases; biological preparations for the treatment of cancer; biological preparations for use in the treatment of autoimmune diseases; pharmaceutical and biological preparations for immunotherapy, including T cell therapy; vaccines. (1) Custom manufacture of therapeutic drugs, namely cell therapies, preparations to treat autoimmune diseases, cancer therapies and cancer vaccines.
(2) Scientific and technological services and research and design relating thereto; industrial analysis and research services; medical and veterinary research services including the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of autoimmune diseases and new cancer therapies; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vaccines, including personalised cancer vaccines; scientific research into vectors and preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services.
(3) Medical services; veterinary services; services in the extraction of human and animal cells from patients; manipulation of human and animal cells for therapeutic purposes; reinsertion of cells into human and animal patients; providing advice and consultancy in the field of medical and veterinary therapies; providing advice and consultancy in the field of autoimmune diseases, cancer therapies and cancer vaccines.
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medical and veterinary preparations for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases for therapeutic purposes; pharmaceutical preparations for cell therapy; pharmaceutical preparations for gene therapy for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; pharmaceutical preparations for cancer therapies; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for treatment of cancer comprising chimeric antigen receptors (CAR) and therapeutic preparations thereof; antibodies for medical purposes; pharmaceutical preparations for genetically modifying human or animal cells for medical purposes, in particular viral vectors; pharmaceutical preparations of blood extracted from humans or animals which have been adapted for therapeutic purposes for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; pharmaceutical preparations for use in the treatment of cancer; pharmaceutical preparations for use in the treatment of autoimmune diseases; biological preparations for the treatment of cancer; biological preparations for use in the treatment of autoimmune diseases; pharmaceutical and biological preparations for immunotherapy, in particular T cell therapy; vaccines Custom manufacture of therapeutic drugs, namely cell therapies, preparations to treat autoimmune diseases, cancer therapies and cancer vaccines Scientific and technological services and research and design relating thereto, namely, medical research, scientific research, analysis and testing in the field of human and animal cell, gene and cancer therapies, pharmaceutical product development, research and development of new products; industrial analysis and research services in the field of cell, gene and cancer therapies; medical and veterinary research services, in particular in the field of the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of autoimmune diseases and new cancer therapies; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vaccines, in particular personalised cancer vaccines; scientific research into vectors and preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services Medical services; veterinary services; medical services for the extraction of human and animal cells from patients; medical services, namely, manipulation of human and animal cells for therapeutic purposes; medical services, namely, reinsertion of cells into human and animal patients; medical and veterinary services, namely, providing advice and consultancy in the field of medical and veterinary therapies; medical and veterinary services, namely, providing advice and consultancy in the field of autoimmune diseases, cancer therapies and cancer vaccines
A method of preparing a population of genetically modified cells which comprise a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR) specific for TCR beta constant region 2 (TRBC2) or TCR beta constant region 1 (TRBC1).
The present invention provides a chimeric antigen receptor (CAR) which binds a target antigen having a bulky extra-cellular domain, wherein the CAR comprises a Fab antigen binding domain. The present invention also provides nucleic acid sequences and constructs encoding such a CAR, cells expressing such a CAR and their therapeutic uses.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides a method of determining the relative potency of a viral vector encoding a chimeric antigen receptor (CAR), the method comprising: a. providing a sample viral vector to be analysed (sample vector) and a reference viral vector of known potency (reference vector); b. transducing separate Effector cell populations with the sample vector and reference vector at various multiplicities of infection (MOIs) to form a group of transduced sample Effector cell populations and a group of transduced reference Effector cell populations; C. conducting cell impedance-based real-time cell killing assays of Target cells using the transduced sample Effector cell populations and the transduced reference cell populations; d. generating a cytotoxicity versus MOI curve for the transduced sample Effector cell populations and for the transduced reference cell populations; e. comparing parallelism of the curves generated in step (d), wherein parallel curves indicate comparable data sets; f. determining the half maximal effective concentration (EC50) of the sample Effector cell population and the reference cell population; and g. comparing the EC50 of the transduced sample Effector cell population and the transduced reference cell population to determine the relative potency of the sample viral vector.
The present invention relates to a chimeric transmembrane protein which provides a cytokine signal to a cell in which it is expressed. The chimeric transmembrane protein comprises an endodomain having a plurality of cytokine-receptor derived tyrosine or threonine motifs, joined together by one or more linker(s). The invention also provides a cell which co-expresses such a chimeric transmembrane protein and a chimeric cytokine receptor (CAR), and its use in the treatment of diseases such as cancer and autoimmune diseases.
The present disclosure relates to the treatment of T Cell Receptor Beta Constant 1 (TRBC1)-positive T-cell malignancies with CAR T cells targeting TRBC1.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides a chimeric antigen receptor (CAR) comprising an anti-TRBC2 antigen-binding domain, a CD28 spacer, a CD28 transmembrane domain, and a CD28- CDSzeta endodomain.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a cell which co-expresses: (i) a first chimeric antigen receptor (CAR) at the cell surface, comprising an antigen-binding domain which binds to CD19; (ii) a second CAR at the cell surface, comprising an antigen-binding domain which binds to CD22; (iii) dominant negative SHP2 (dSHP2); and (iv) dominant negative TGFβ receptor II (dnTGFβRII).
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
The present invention provides a nucleic acid construct comprising: a first nucleotide sequence of interest (NOI1); a frame-slip motif or a translational readthrough motif (FSM/TRM); and a second nucleotide sequence of interest (NOI2). The invention also provides vectors and cells expressing such a construct. The invention also provides a method for modulating the relative expression of two transgenes in a nucleic acid construct which comprises the step of including a frame-slip motif or a translational readthrough motif between the two transgenes in order to reduce the expression of the downstream transgene.
09 - Scientific and electric apparatus and instruments
41 - Education, entertainment, sporting and cultural services
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Downloadable mobile applications for use in enabling healthcare professionals and patients to access information on pharmaceutical and medical related products and services. Educational services, in particular, training and coaching services in the field of medical diseases and disorders and their treatment; arranging, organising and conducting events for educational purposes related to oncology, autoimmune diseases, immunotherapy and cell therapy Hosting a website featuring non-downloadable software for use as a digital platform tailored to healthcare professionals and patients for facilitating web-based appointment scheduling, medical consultation, medical examination, health assessment, health education, supervising, monitoring and treatment of patients in a remote setting, coordinating patients' care and medical resources, and secure messaging to patients and healthcare providers; software as a service(SaaS) services featuring software for use as a digital platform tailored to healthcare professionals and patients for facilitating web based appointment scheduling, medical consultation, medical examination, health assessment, health education, supervising, monitoring and treatment of patients in a remote setting, coordinating patients' care and medical resources, and secure messaging to patients and healthcare providers; platform as a service (PaaS) services featuring computer software platforms tailored to healthcare professionals and patients for facilitating web-based appointment scheduling, medical consultation, medical examination, health assessment, health education, supervising, monitoring and treatment of patients in a remote setting, coordinating patients' care and medical resources, and secure messaging to patients and healthcare providers; provision of scientific information via an internet portal Medical and healthcare services; providing medical information related to healthcare, pharmaceutical products, vaccines, diseases and disorders and treatment options via a website and platform; medical services related to providing support for patients and healthcare providers featuring information in the field of healthcare, oncology, autoimmune diseases, immunotherapy, cell therapy and pharmaceutical products via a website and platform; providing medical information via a website, namely clinical and medical information, including providing advice on patient specific pharmaceuticals and cell therapies, disease monitoring and treatment in the field of oncology, autoimmune diseases, immunotherapy and cell therapy; provision of medical information, consultancy and advisory services relating to all of the aforesaid services
31.
A CHIMERIC CYTOKINE RECEPTOR, WHICH COMPRISES A TRUNCATED IL2RBETA AND IL2RGAMMA
The present invention provides a chimeric cytokine receptor comprising a cytokine receptor endodomain which comprises a first chain and a second chain, wherein both the first and second chain of the cytokine-receptor endodomain are truncated. The invention also provides cells comprising such a chimeric cytokine receptor, optionally in combination with a chimeric antigen receptor (CAR) and their use in the treatment of diseases such as autoimmune diseases and cancer.
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
32.
CELL EXPRESSING A CAR AND A TRANSCRIPTION FACTOR AND ITS USE
The present invention provides a cell which comprises a first exogenous nucleic acid molecule encoding a Chimeric Antigen Receptor (CAR) and a second exogenous nucleic acid molecule encoding a transcription factor.
The present invention provides a kit of vectors for transducing an immune cell with multiple transgenes comprising: (i) a first vector which comprises a first transgene and a nucleotide sequence encoding a transcription factor and; and (ii) a second vector which comprises a second transgene wherein expression of the second transgene within a host cell is dependent upon expression of the transcription factor.
Provision of a chimeric antigen receptor (CAR) comprising a disialoganglioside (GD2)-binding domain which comprises⋅a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences:⋅b) a light chain variable region (VL) having CDRs with the following sequences: T cells expressing such a CAR are useful in the treatment of some cancers.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The present disclosure relates to antigen-binding domains which bind the antigen prostate-specific membrane antigen (PSMA) and to chimeric antigen receptors (CARs) which comprise such antigen binding domains.
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The present invention provides a chimeric antigen receptor (CAR) comprising: a. an antigen-binding domain; b. a spacer; c. a transmembrane domain; d. an intracellular signalling domain; wherein the spacer comprises SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49 or SEQ ID NO: 50, or a variant thereof having 1-5 amino acid modifications.
The invention relates to a method comprising (a) providing a vertebrate somatic cell, (b) inducing expression in said cell of at least three transcription factors, wherein said transcription factors are: i. Tbet (Tbx21), ii. Tcf7, and iii. Ets1; (c) incubating said cell to allow transdifferentiation. Suitably said cell is transdifferentiated to an immune effector cell. The invention also relates to cells, nucleic acids, pharmaceutical compositions, and methods of treatment.
The present invention relates to an engineered immune cell which comprises: (i) a target binding polypeptide comprising a target-binding domain and a first protein interaction domain, and (ii) a localising polypeptide comprising a second protein interaction domain, which binds to the first protein binding domain, and an intracellular retention signal. When the target binding polypeptide binds its target protein and also the localising polypeptide, expression of the target protein at the cell surface is reduced or eliminated because the target protein is retained in an intracellular compartment.
C07K 14/74 - Major histocompatibility complex [MHC]
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
The present invention provides a retroviral or lentiviral vector having a viral envelope which comprises a mitogenic T-cell activating transmembrane protein which comprises: (i) a mitogenic domain which binds a mitogenic tetraspanin, and (ii) a transmembrane domain; wherein the mitogenic T-cell activating transmembrane protein is not part of a viral envelope glycoprotein. When cells such as T-cells or Natural Killer cells are transduced by such a viral vector, they are activated by the mitogenic T-cell activating transmembrane protein.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to a cell comprising a chimeric antigen receptor (CAR) and a constitutively active or inducible Signal Transducer and Activator of Transcription (STAT) molecule.
C12N 15/62 - DNA sequences coding for fusion proteins
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The present invention provides a chimeric antigen receptor (CAR) comprising: (i) a B cell maturation antigen (BCMA)-binding domain which comprises at least part of a proliferation-inducing ligand (APRIL); (ii) a spacer domain (iii) a transmembrane domain; and (iv) an intracellular T cell signaling domain. The invention also provides the use of such a T-cell expressing such a CAR in the treatment of plasma-cell mediated diseases, such as multiple myeloma.
The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising: (i) an antigen-binding domain; (ii) a spacer (iii) a trans-membrane domain; and (iv) an endodomain wherein the antigen binding domains of the first and second CARs bind to different antigens, and wherein each of the first and second CARs is an activating CAR comprising an activating endodomain.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising: (i) an antigen-binding domain; (ii) a spacer (iii) a transmembrane domain; and (iv) an endodomain wherein the antigen binding domains of the first and second CARs bind to different antigens, wherein the spacer of the first CAR is different to the spacer of the second CAR and wherein one of the first or second CARs is an activating CAR comprising an activating endodomain and the other CAR is an inhibitory CAR comprising a ligation-off inhibitory endodomain.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
The invention relates to antibodies or antigen-binding fragments thereof that specifically bind to the receptor binding domain (RBD) region of the SARS-CoV-2 Spike (S) protein. The invention further relates to methods for treating or preventing SARS-CoV-2 infection and related medical uses of the antibodies or antigen-binding fragments thereof.
The present invention relates to a cell which expresses a tri-specific chimeric antigen receptor (CAR) with multiple antigen specificities. The cell targets multiple antigens characteristic of acute myeloid leukemia (AML), specifically CD33, CD123, and CLL1.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides a method of preparing a population of genetically modified cells which comprise a chimeric antigen receptor (CAR) or a transgenic T- cell receptor (TCR) comprising: (i) providing a starting population of cells; (ii) depleting said starting population of cells which express a target antigen to form a depleted starting population; (iii) selecting for CD4+ and CD8+ cells in the depleted starting population to form a selected population of cells; and (iv) introducing into a cell in the selected population a nucleic acid sequence which encodes a CAR or transgenic TCR against the target antigen.
The present disclosure relates to CD19/22 CAR T-cell products and methods for treating high risk or relapsed CD19+ or CD22+ haemotological malignancies.
The present invention provides a chimeric antigen receptor (CAR) comprising an antigen-binding domain with an affinity in the range of 50 nM to 500 nM, wherein said affinity comprises component kinetics such that the association rate constant (kon) is greater than or equal to 1×105 M−1 S−1, and/or the dissociation rate constant (koff) is greater than or equal to 0.01 s−1.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides a method for treating a disease in a subject, which comprises the step of administering to the subject a plurality of cells which express: (a) a chimeric antigen receptor (CAR); and (b) a mutant version of calcineurin A and/or calcineurin B which is resistant to the calcineurin inhibitor. The subject may be receiving or have received treatment with a calcineurin inhibitor. The CAR-expressing cells may be administered prior to, following, simultaneously with or in combination with a calcineurin inhibitor.
The present disclosure provides a cell comprising: an anti-CD33 chimeric antigen receptor (CAR); an anti-CLL1 CAR; and an anti- CD123 and/or anti- CAR FLT3 CAR. The cell can be used in the treatment of a disease such as acute myeloid leukemia (AML).
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 35/02 - Antineoplastic agents specific for leukemia
51.
Cell lexpressing two chimeric antigen receptors (CARs) at the cell surface
The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising an antigen-binding domain, wherein the antigen-binding domain of the first CAR binds to CD19 and the antigen-binding domain of the second CAR binds to CD22.
A61K 35/00 - Medicinal preparations containing materials or reaction products thereof with undetermined constitution
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medical and veterinary preparations for therapeutic
purposes; preparations for cell therapy; preparations for
gene therapy; preparations for cancer therapies; chimeric
antigen receptors (CAR) and therapeutic preparations
thereof; antibodies; preparations for genetically modifying
human or animal cells for medical purposes, including viral
vectors; preparations of blood extracted from humans or
animals which have been adapted for therapeutic purposes;
vaccines. Custom manufacture of therapeutic drugs, namely cell
therapies, cancer therapies and cancer vaccines. Scientific and technological services and research and
design relating thereto; industrial analysis and research
services; medical and veterinary research services including
the manipulation of cells within a laboratory or research
facility to enable the cells to be used for therapeutic
purposes; scientific research in the development of new
cancer therapies; scientific research in human and animal
cell therapy; scientific research in human and animal gene
therapy; scientific research into vaccines, including
personalised cancer vaccines; scientific research into
vectors and preparations for manipulating and adapting human
and animal cells; consultancy relating to all the aforesaid
services. Medical services; veterinary services; services in the
extraction of human and animal cells from patients;
manipulation of human and animal cells for therapeutic
purposes; reinsertion of cells into human and animal
patients; providing advice and consultancy in the field of
medical and veterinary therapies; providing advice and
consultancy in the field of cancer therapies and cancer
vaccines.
The present invention provides polypeptides with coronavirus neutralising capacity. It further provides nucleic acids, vectors, cells, pharmaceutical compositions and medical uses that exploit the polypeptides of the invention
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Medical and veterinary preparations, namely, engineered T-cells for medical therapeutic purposes; preparations for cell therapy, namely, engineered T-cells for medical cell therapy; preparations for gene therapy; preparations for cancer therapies; chimeric antigen receptors (CAR) and therapeutic preparations thereof; therapeutic antibodies for use as immunotherapeutic agents; preparations for genetically modifying human and animal cells for medical purposes, consisting of viral vectors for use in the treatment of cancer, genetic conditions, immune response disorders, autoimmune diseases, infectious diseases, namely, respiratory infections, topical infections, blood infections; biological preparations made from human and animal blood cells which have been adapted for therapeutic purposes, for use in the treatment of cancer, genetic conditions, immune response disorders, autoimmune diseases, infectious diseases, namely, respiratory infections, topical infections, blood infections; human pharmaceutical vaccines (1) Custom manufacture of therapeutic drugs, namely cell therapies, cancer therapies and cancer vaccines.
(2) Scientific and technological services and research and design relating thereto, namely scientific research in the field of cell and gene therapies; industrial analysis and research services in the field of T-cells and chimeric antigen receptors; medical and veterinary research services namely, medical and veterinary research in the manipulation of cells within a laboratory and research facility to enable the cells to be used for therapeutic purposes in the field of cell therapy; scientific research in the development of new cancer therapies; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vaccines, including personalised cancer vaccines; scientific research into vectors and preparations for manipulating and adapting human and animal cells; consultancy relating to cell and gene therapies for third parties.
(3) Medical services in the field of cell and gene therapies; veterinary services in the field of cell and gene therapies; services in the extraction of human and animal cells from patients; manipulation of human and animal cells for therapeutic purposes; reinsertion of cells into human and animal patients for medical purposes; providing advice and consultancy in the field of medical and veterinary cell and gene therapies; providing advice and consultancy in the field of cancer therapies and cancer vaccines.
05 - Pharmaceutical, veterinary and sanitary products
40 - Treatment of materials; recycling, air and water treatment,
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medical and veterinary preparations for therapeutic purposes for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; medical preparations for cell therapy for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; medical preparations for gene therapy for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; medical preparations for cancer therapies for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; cells for medical or clinical use, namely, cells featuring chimeric antigen receptors (CAR) and therapeutic preparations thereof for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; antibodies for medical purposes for the treatment of cancer, genetic conditions, immune response disorders, autoimmune disorders, infectious diseases, ophthalmological conditions, hematologic diseases, neurological disorders, respiratory diseases, metabolic diseases and cardiovascular diseases; preparations for genetically modifying human or animal cells for medical purposes, including viral vectors, namely, culture media for cultivating and augmentation of human and animal cells; preparations of blood extracted from humans or animals which have been adapted for therapeutic purposes; vaccines Custom manufacture of therapeutic drugs, namely, cell therapies, cancer therapies and cancer vaccines Scientific and technological services and research and design relating thereto, namely, medical research, scientific research, analysis and testing in the field of human and animal cell, gene and cancer therapies, pharmaceutical product development, research and development of new products; industrial analysis and research services in the field of cell, gene and cancer therapies; medical and veterinary research services including the manipulation of cells within a laboratory or research facility to enable the cells to be used for therapeutic purposes; scientific research in the development of new cancer therapies; scientific research in human and animal cell therapy; scientific research in human and animal gene therapy; scientific research into vaccines, including personalised cancer vaccines; scientific research into vectors and preparations for manipulating and adapting human and animal cells; consultancy relating to all the aforesaid services Medical services; veterinary services; medical and veterinary services in the nature of extraction of human and animal cells from patients; manipulation of human and animal cells for therapeutic purposes, namely, medical services relating to the removal, treatment and processing of human and animal cells; medical and veterinary services in the nature of reinsertion of cells into human and animal patients; providing medical advice and consultancy in the field of medical and veterinary therapies; providing advice and consultancy in the field of cancer therapies and cancer vaccines
The present invention provides a method for treating a solid cancer which comprises the step of administering a cell to a subject, wherein the cell comprises a nucleic acid sequence encoding interleukin 12 (IL-12) downstream of a frame-slip motif (FSM) or a translational readthrough motif (TRM).
There is provided a plasmid system for transfection into a cell to create a producer cell, the system comprising: a. a helper plasmid comprising a first nucleotide sequence encoding Murine leukemia virus (MLV)-derived Gag and Pol poly-proteins; b. an envelope plasmid comprising a second nucleotide sequence encoding an Env protein; c. a genome plasmid comprising a third nucleotide sequence encoding a retroviral genome, wherein the first nucleotide sequence is codon-shuffled to remove any significant regions of homology with the third nucleotide sequence; and wherein the second nucleotide sequence is codon-optimised for expression in the producer cell.
The present invention provides a nucleic acid construct comprising: a first nucleotide sequence of interest (NOI1); a UGA-CUAGCA motif (SEQ ID No. 1); and a second nucleotide sequence of interest (NOI2). The invention also provides vectors and cells expressing such a construct.
The present invention provides cell which co-expresses a chimeric antigen receptor (CAR) and a dominant negative C-terminal Src kinase (dnCSK). The present invention also provides nucleic acid constructs, vectors and methods for making such a cell and the use of such a cell in the treatment of diseases such as cancer by adoptive immunotherapy.
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
There is provided a chimeric antigen receptor (CAR) comprising a CD19-binding domain which comprises a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: CDR1—GY-AFSSS (SEQ ID No. 1); CDR2—YPGDED (SEQ ID No. 2) CDR3—SLLYGDYLDY (SEQ ID No. 3); and b) a light chain variable region (VL) having CDRs with the following sequences: CDR1—SASSSVSYMH (SEQ ID No. 4); CDR2—DTSKLAS (SEQ ID No. 5) CDR3—QQWNINPLT (SEQ ID No. 6). There is also provided a cell comprising such a CAR, and the use of such a cell in the treatment of cancer, in particular a B cell malignancy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medical and veterinary preparations for therapeutic
purposes; preparations for cell therapy; preparations for
gene therapy; preparations for cancer therapies; chimeric
antigen receptors (CAR) and therapeutic preparations
thereof; antibodies; preparations for genetically modifying
human or animal cells for medical purposes, including viral
vectors; preparations of blood extracted from humans or
animals which have been adapted for therapeutic purposes;
pharmaceutical preparations; pharmaceutical preparations for
use in the treatment of cancer; biological preparations for
the treatment of cancer; pharmaceutical and biological
preparations for immunotherapy, including T cell therapy;
vaccines.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medical and veterinary preparations for therapeutic
purposes; preparations for cell therapy; preparations for
gene therapy; preparations for cancer therapies; chimeric
antigen receptors (CAR) and therapeutic preparations
thereof; antibodies; preparations for genetically modifying
human or animal cells for medical purposes, including viral
vectors; preparations of blood extracted from humans or
animals which have been adapted for therapeutic purposes;
pharmaceutical preparations; pharmaceutical preparations for
use in the treatment of cancer; biological preparations for
the treatment of cancer; pharmaceutical and biological
preparations for immunotherapy, including T cell therapy;
vaccines.
There is provided an effector immune cell which expresses a cell surface receptor or receptor complex which specifically binds an antigen recognition receptor of a target immune cell; which effector immune cell is engineered such that when a synapse is formed between the effector immune cell and the target immune cell, the capacity of the effector immune cell to kill the target immune cell is greater than the capacity of the target immune cell to kill the effector immune cell. There is also provided the use of such a cell in methods for treating cancer, preventing allograft rejection and GVHD.
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
65.
Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof
The present invention provides a chimeric cytokine receptor (CCR) comprising: (i) an exodomain which binds to a ligand selected from a tumour secreted factor, a chemokine and a cell-surface antigen; and (ii) a cytokine receptor endodomain.
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/46 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
The present invention provides a method for selecting for cells transduced to express a nucleic acid sequence of interest (NOI), which comprises the following steps: (a) transducing a population of cells with a vector co-expressing the NOI and a nucleic acid sequence which inhibits Fas expression or activity in the cell; (b) exposing the cells from (a) to FasL such that untransduced cells are eliminated by apoptosis. The present invention also provides a molecule which comprises a Fas-binding domain linked to an intracellular retention signal which may be used in such a method to inhibit Fas expression.
The present invention provides a chimeric cytokine receptor (CCR) which comprises two polypeptides: (i) a first polypeptide which comprises: (a) an ectodomain which comprises a first dimerization domain; (b) an interleukin-18 receptor 1 (IL18R1) endodomain; and (ii) a second polypeptide which comprises: (a) an ectodomain which comprises a second dimerization domain; (b) an interleukin-18 receptor accessory protein (IL18RAP) endodomain. The first polypeptide and the second polypeptide spontaneously dimerise causing IL18-type signalling to occurs through the IL18R1 and IL18RAP endodomains. The invention also provides a cell comprising such a CCR and optionally a chimeric antigen receptor (CAR) and the use of such a cell in the treatment of e.g. cancer or an autoimmune disease.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medical and veterinary preparations for therapeutic purposes for the treatment of cancer, genetic conditions, immune response disorders, autoimmune diseases and infectious diseases; medical preparations for cell therapy for the treatment of cancer, genetic conditions, immune response disorders, autoimmune diseases and infectious diseases; medical preparations for gene therapy for the treatment of cancer, genetic conditions, immune response disorders, autoimmune diseases and infectious diseases; medical preparations for cancer therapies for the treatment of cancer, genetic conditions, immune response disorders, autoimmune diseases and infectious diseases; cells for medical or clinical use, namely cells featuring chimeric antigen receptors (CAR) and therapeutic preparations thereof for the treatment of cancer, genetic conditions, immune response disorders, autoimmune diseases and infectious diseases; antibodies for medical purposes for the treatment of cancer, genetic conditions, immune response disorders, autoimmune diseases and infectious diseases; preparations for genetically modifying human or animal cells for medical purposes, including viral vectors, namely, culture media for cultivating and augmentation of human and animal cells; preparations of blood extracted from humans or animals which have been adapted for therapeutic purposes; pharmaceutical preparations for use in the treatment of cancer; biological preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including T cell therapy; vaccines
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Medical and veterinary preparations for therapeutic purposes for the treatment of cancer, genetic conditions, immune response disorders, autoimmune diseases and infectious diseases; medical preparations for cell therapy for the treatment of cancer, genetic conditions, immune response disorders, autoimmune diseases and infectious diseases; medical preparations for gene therapy for the treatment of cancer, genetic conditions, immune response disorders, autoimmune diseases and infectious diseases; medical preparations for cancer therapies for the treatment of cancer, genetic conditions, immune response disorders, autoimmune diseases and infectious diseases; cells for medical or clinical use, namely cells featuring chimeric antigen receptors (CAR) and therapeutic preparations thereof for the treatment of cancer, genetic conditions, immune response disorders, autoimmune diseases and infectious diseases; antibodies for medical purposes for the treatment of cancer, genetic conditions, immune response disorders, autoimmune diseases and infectious diseases; preparations for genetically modifying human or animal cells for medical purposes, including viral vectors, namely, culture media for cultivating and augmentation of human and animal cells; preparations of blood extracted from humans or animals which have been adapted for therapeutic purposes; pharmaceutical preparations for use in the treatment of cancer; biological preparations for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including T cell therapy; vaccines
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Medical and veterinary preparations, namely, engineered T-cells for medical therapeutic purposes; preparations for cell therapy, namely, engineered T-cells for medical cell therapy; preparations for gene therapy; preparations for cancer therapies; chimeric antigen receptors (CAR) and therapeutic preparations thereof; therapeutic antibodies for use as immunotherapeutic agents; preparations for genetically modifying human and animal cells for medical purposes, consisting of viral vectors for use in the treatment of cancer, genetic conditions, immune response disorders, autoimmune diseases, infectious diseases, namely, respiratory infections, topical infections, blood infections; biological preparations made from human and animal blood cells which have been adapted for therapeutic purposes, for use in the treatment of cancer, genetic conditions, immune response disorders, autoimmune diseases, infectious diseases, namely, respiratory infections, topical infections, blood infections; pharmaceutical preparations for use in the treatment of cancer, genetic conditions, immune response disorders, autoimmune diseases, infectious diseases, namely, respiratory infections, topical infections, blood infections; pharmaceutical preparations for use in the treatment of cancer; biological preparations, namely, engineered T-cells for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including T cell therapy; human pharmaceutical vaccines
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Medical and veterinary preparations, namely, engineered T-cells for medical therapeutic purposes; preparations for cell therapy, namely, engineered T-cells for medical cell therapy; preparations for gene therapy; preparations for cancer therapies; chimeric antigen receptors (CAR) and therapeutic preparations thereof; therapeutic antibodies for use as immunotherapeutic agents; preparations for genetically modifying human and animal cells for medical purposes, consisting of viral vectors for use in the treatment of cancer, genetic conditions, immune response disorders, autoimmune diseases, infectious diseases, namely, respiratory infections, topical infections, blood infections; biological preparations made from human and animal blood cells which have been adapted for therapeutic purposes, for use in the treatment of cancer, genetic conditions, immune response disorders, autoimmune diseases, infectious diseases, namely, respiratory infections, topical infections, blood infections; pharmaceutical preparations for use in the treatment of cancer, genetic conditions, immune response disorders, autoimmune diseases, infectious diseases, namely, respiratory infections, topical infections, blood infections; pharmaceutical preparations for use in the treatment of cancer; biological preparations, namely, engineered T-cells for the treatment of cancer; pharmaceutical and biological preparations for immunotherapy, including T cell therapy; human pharmaceutical vaccines
The present invention relates to a cell which comprises; (a) a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR); and (b) a FasL-binding receptor (FLBR) comprising; (i) a Fas ectodomain and a TNFR endodomain, wherein the TNFR endodomain comprises the signalling portion of the decoy receptor 2 (DcR2), GITR, CD30, XEDAR, CD40, CD27, BCMA or Fn14 endodomain, or (ii) a membrane-bound decoy receptor 3 (DcR3).
The present disclosure provides an antibody conjugate that binds specifically to TCR beta constant region (TRBC), wherein the antibody has a fast dissociation rate constant (kd). It further provides medical uses and methods of personalised medicine that exploit the products of the invention.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 35/02 - Antineoplastic agents specific for leukemia
The present invention relates to engineered a cytolytic immune cell comprising: i) a releasable protein which comprises a polypeptide of interest (POI) and a first interaction domain; and ii) a retention protein which is retained within an intracellular compartment of the cell and comprises a second interaction domain which binds to the first protein interaction domain, wherein binding between the first protein interaction domain and second protein interaction domain is disrupted by the presence of an agent, such that in the absence of the agent, the first protein interaction domain and second protein interaction domain bind and result in retention of the POI within an intracellular compartment; whereas in the presence of the agent, the first protein interaction domain and second protein interaction do not bind and the POI is released from the intracellular compartment and expressed at the cell surface or secreted by the cell.
The present disclosure relates to anti-TRBCl antigen binding domains characterized by the sequences of the variable chains. The CDRs sequences of the variable chains are: (VH CDR1) GYTFT, (VH CDR2) NPYNDDIQS, (VH CDR3) GAGY-NFDGAYRFFDF; and (VL CDR1) RSSQRLVHSNGNTYL, (VL CDR2) RVSNRFP, (VL CDR3) SQSTHVPYT. The claimed humanized antibodies derive from the murine JOVI antibody. Uses in cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TOR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
The present invention relates to FcRH5 binding domains. In particular, the invention provides single domain antibodies, antibody conjugates, chimeric antigen receptors (CARs) and immune cell engagers which comprise such binding domains.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
There is provided method for making a cell composition which comprises step of transducing a population of cells with a mixture of at least two viral vectors, wherein at least one vector comprises a nucleic acid sequence which encodes a chimeric antigen receptor (CAR); and wherein at least one vector comprises a nucleic acid encoding an activity modulator which modulates the activity of the CAR, of a cell expressing the CAR, or of a target cell. There is also provided a cell composition made by such a method and its use in the treatment of diseases such as cancer.
The present invention provides a chimeric antigen receptor (CAR) which binds a low density target antigen, which comprises a Fab antigen binding domain. The invention also relates to cells expressing such a CAR and their use in the treatment of disease.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
The present invention provides a chimeric antigen receptor (CAR) system comprising: (i) a first receptor component comprising: a Fab light chain or a Fab heavy chain; a transmembrane domain; and a first binding domain; (ii) a second receptor component comprising either: a Fab heavy chain when the first receptor component comprises a Fab light chain; or a Fab light chain when the first receptor component comprises a Fab heavy chain; such that the first and second receptor components heterodimerise to form a heterodimeric receptor component comprising an antigen binding domain; and (ii) an intracellular signalling component comprising: a signalling domain; and a second binding domain which specifically binds the first binding domain; wherein, binding of the first and second binding domains is disrupted by the presence of an agent, such that in the absence of the agent the heterodimeric receptor component and the signalling component heterodimerize and binding of the antigen binding domain to antigen results in signalling through the signalling domain, whereas in the presence of the agent the heterodimeric receptor component and the signalling component do not heterodimerize and binding of the antigen binding domain to antigen does not result in signalling through the signalling domain.
The present invention provides a chimeric cytokine receptor comprising a cytokine receptor endodomain which comprises a first chain and a second chain, wherein the first and/or second chain of the cytokine-receptor endodomain is/are truncated. The invention also provides cells comprising such a chimeric cytokine receptor, optionally in combination with a chimeric antigen receptor (CAR) and their use in the treatment of diseases such as cancer.
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
The invention relates to a method comprising (a) providing a vertebrate somatic cell, (b) inducing expression in said cell of at least three transcription factors, wherein said transcription factors are: i. Tbet (Tbx21), ii. Tcf7, and iii. Ets1; (c) incubating said cell to allow transdifferentiation. Suitably said cell is transdifferentiated to an immune effector cell. The invention also relates to cells, nucleic acids, pharmaceutical compositions, and methods of treatment.
The present invention provides a chimeric receptor which comprises: a ligand-binding exodomain; and an endodomain which comprises: (i) a cytokine receptor endodomain; and (ii) an intracellular T cell signalling domain.
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
The present invention provides a chimeric antigen receptor (CAR) which specifically binds CD79 as well as a nucleic acid sequence and a vector encoding the CAR. It further provides a cell which expresses the CAR at the cell surface.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention relates to a cell which comprises a chimeric antigen receptor (CAR) and a signal transduction modifying protein, selected from one of the following: (i) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM), but lacks a kinase domain; (ii) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM) but lacks a phosphatase domain; (iii) a fusion protein which comprises (a) an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM) or from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM); and (ii) a heterologous domain.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
The present invention provides a chimeric antigen receptor (CAR) which binds a target antigen having a bulky extracellular domain, wherein the CAR comprises a Fab antigen binding domain. The present invention also provides nucleic acid sequences and constructs encoding such a CAR, cells expressing such a CAR and their therapeutic uses.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides a virus-like particle (VLP) having a viral envelope which comprises: (i) a membrane protein comprising the extracellular domain of CD86; and (ii) a CD3-binding membrane protein. The VLP may be used to activate T cells prior to viral transduction.
The present invention provides a molecule which comprises a Fas-binding domain linked to an intracellular retention signal. When expressed in a cell, the molecule inhibits Fas expression at the cell surface and therefore Fas:FasL-mediated apoptosis.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The present invention provides a cell which expresses a chimeric antigen receptor (CAR) or engineered T-cell receptor (TCR) and secretes an agent which blocks or reduces the activity of an ectoenzyme. The cells may be used in adoptive immunotherapy approaches for the treatment of diseases such as cancer.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides a method for the production of a recombinant lentiviral vector, comprising: (a) inoculating serum-free media in a rocking motion bioreactor with human cells; (b) expanding the cells for from 1 to 4 days; (c) transfecting the cells with at least one plasmid adapted for the production of a lentiviral vector; (d) inducing the cells with an induction agent; (e) adjusting the pH of the media to from 6.2 to 7.0, preferably to from 6.4 to 6.8, most preferably to 6.8; (f) expanding the cells for from 2 to 8 days while harvesting the produced recombinant lentiviral vector from the culture medium by perfusion through a perfusion membrane; and (g) optionally purifying the recombinant lentiviral vector.
The present invention provides a cell which comprises; (i) a chimeric antigen receptor (CAR) or a transgenic T-cell receptor (TCR); and (ii) at least one polypeptide capable of co-localizing an MHC class I polypeptide or an MHC class II polypeptide with an intracellular signalling domain within the cell.
There is provided method for making a cell composition which comprises step of transducing a population of cells with a mixture of at least two viral vectors, wherein at least one vector comprises a nucleic acid sequence which encodes a chimeric antigen receptor (CAR); and wherein at least one vector comprises a nucleic acid encoding an activity modulator which modulates the activity of the CAR, of a cell expressing the CAR, or of a target cell. There is also provided a cell composition made by such a method and its use in the treatment of diseases such as cancer.
The present invention provides a polypeptide comprising an amino acid sequence of at least one receptor-binding domain (RBD) of a viral Spike protein, a spacer and a transmembrane domain. It further provides nucleic acids, nucleic acid constructs, expression cassettes, vectors, cells, pharmaceutical compositions and medical uses that exploit the polypeptides of the invention.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
The present invention provides a nucleic acid construct comprising: a first nucleotide sequence of interest (NOI1); a frame-slip motif or a translational readthrough motif (FSM/TRM); and a second nucleotide sequence of interest (NOI2). The invention also provides vectors and cells expressing such a construct. The invention also provides a method for modulating the relative expression of two transgenes in a nucleic acid construct which comprises the step of including a frame-slip motif or a translational readthrough motif between the two transgenes in order to reduce the expression of the downstream transgene.
The present disclosure relates to anti-TRBC1 antigen binding domains characterized by the sequences of the variable chains. The CDRs sequences of the variable chains are: (VH CDR1) GYTFT, (VH CDR2) NPYNDDIQS, (VH CDR3) GAGYNFDGAYRFFDF; and (VL CDR1) RSSQRLVHSNGNTYL, (VL CDR2) RVSNRFP, (VL CDR3) SQSTHVPYT. The claimed humanized antibodies derive from the murine JOVI antibody. Uses in cancer therapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes
C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention relates to the use of an IL-1β inhibitor for the prevention and/or treatment of neurotoxicity and/or cytokine release syndrome in a subject undergoing immunotherapy, wherein the IL-1β inhibitor is administered before immunotherapy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides an engineered cell, such as a T-cell, which expresses a chimeric antigen receptor (CAR) or an engineered T-cell receptor (TCR) and one or more enzymes which, when secreted or expressed at the cell surface causes depletion of a molecule extracellular to the engineered cell; wherein said molecule is selected from: an amino acid; a nucleotide or nucleoside; or a lipid.
